Company Website: http://www.dendreon.com
SEATTLE -- (Business Wire)

May 25, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the following conferences:

• Jefferies 2012 Global Healthcare Conference in New York City on June 4, 2012, at 12:30 p.m. ET
• Goldman Sachs Global Healthcare Conference 2012 in Rancho Palos Verdes, CA, on June 5, 2012, at 11:20 a.m. PT
• NASDAQ OMX 28th Investor Program in London, UK, on June 26, 2012, at 2:15 p.m. GMT

The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

Contacts:

Dendreon Corporation
Investor Relations:
Nicole Soley, 206-455-2220
InvestorRelations@dendreon.com

Source: Dendreon Corporation